Exploring the Impact of Helicobacter pylori and Potential Gut Microbiome Modulation
Helicobacter pylori is a highly prevalent bacteria that can harm humans due to its major involvement in developing gastrointestinal diseases, particularly gastric cancer. Therefore, eradicating H. pylori is one of the most important strategies for preventing gastric cancer. Antibiotic treatment has always been the gold standard treatment for H. pylori infection. However, the decreasing efficacy of antibiotic therapy due to the rising antibiotic resistance and high incidence of dysbiosis-related adverse effects resulted in eradication failure. To enhance the effectiveness of antibiotic therapy, strategies that modulate the gut microbiome were proposed to play a positive role. Generally, the integration of probiotics or symbiotic into antibiotic therapy was shown to enhance the eradication rate and reduce the incidence of adverse effects. This review aims to discuss the role and effect of H. pylori in gastric carcinogenesis and gut microbiome modulation in eradicating H. pylori infection.
Copyright (c) 2023 Isaac Jingkhai Ong, Ke-Yan Loo, Lydia Ngiik-Shiew Law, Jodi Woan-Fei Law, Loh Teng-Hern Tan, Vengadesh Letchumanan
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Author(s) shall retain the copyright of their work and grant the Journal/Publisher right for the first publication with the work simultaneously licensed under:
Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). This license allows for the copying, distribution and transmission of the work, provided the correct attribution of the original creator is stated. Adaptation and remixing are also permitted.
This broad license intends to facilitate free access to, as well as the unrestricted reuse of, original works of all types for non-commercial purposes.
The author(s) permits HH Publisher to publish this article that has not been submitted elsewhere.